Logo

Innovent Presents Results of Sintilimab + Byvasda (biosimilar, bevacizumab) in P-III ORIENT-31 Study for EGFR-Mutated Non squamous NSCLC at ESMO 2021

Share this

Innovent Presents Results of Sintilimab + Byvasda (biosimilar, bevacizumab) in P-III ORIENT-31 Study for EGFR-Mutated Non squamous NSCLC at ESMO 2021

Shots:

  • The P-III ORIENT-31 study evaluates sintilimab with/out Byvasda (bevacizumab biosimilar inj.) + CT vs CT alone in a ratio (1:1:1) in patients with EGFR-mutated LA or metastatic nsq.NSCLC who have progressed following EGFR TKI treatment
  • The results showed an improvement in PFS at 1st interim analysis in ITT population, m-PFS (6.9mos. & 4.3mos.) with numerical benefit & 2EPs showed an improvement in ORR & DoR, PFS data was immature. The safety profile was consistent with previously reported studies of sintilimab & Byvasda (biosimilar Avastin) & no new safety signals were observed
  • The company plans to file the sNDA to NMPA shortly & has 2 regulatory submissions which are accepted for review in China for sintilimab monothx. to treat ESCC

/ article | Ref: PR Newswire | Image:Innovent

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions